Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
Fisher B, Zaoutis T, Xiao R, Wattier R, Castagnola E, Pana Z, Fullenkamp A, Boge C, Ross R, Yildirim I, Palazzi D, Danziger-Isakov L, Vora S, Arrieta A, Yin D, Avilés-Robles M, Sharma T, Tribble A, Maron G, Berman D, Green M, Sung L, Romero J, Hauger S, Roilides E, Belani K, Nolt D, Soler-Palacin P, López-Medina E, Muller W, Halasa N, Dulek D, Bin Hussain I, Pong A, Hoffman J, Rajan S, Gonzalez B, Hanisch B, Aftandilian C, Carlesse F, Abzug M, Huppler A, Salvatore C, Ardura M, Chakrabarti A, Santolaya M, Localio A, Steinbach W. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 994-1003. PMID: 34374424, DOI: 10.1093/jpids/piab024.Peer-Reviewed Original ResearchAmphotericin B formulationsInvasive candidiasisAmphotericin B groupRisk differenceExposure groupB formulationsMultinational observational cohort studyCommon invasive fungal diseaseCrude failure rateData review committeeObservational cohort studyB groupInvasive fungal diseaseMantel-Haenszel analysisCohort studyPrimary outcomePrimary exposureFailure rateComparative effectivenessCandidiasisTherapyEffectiveness dataEchinocandinsReview CommitteeChildren
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply